If MNTA signed the deal calling for anything more than a marginally lower profit share should Sanofi launch an authorized generic, that was a major gaffe. How to control what Sanofi will decide to do? If multiple generics are approved then no doubt nvs is out a lot of money and mnta deserves only a modest single digit royalty.
Market Data 
Markets 
AI
